BeiGene Approved to Launch BTK Inhibitor in China for Two Cancer Indications

BeiGene, a Beijing cancer biotech, announced China's NMPA approved its BTK inhibitor, Brukinsa™ (zanubrutinib), for two cancer indications: chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). All indications are for second-line treatment in adult patients. In late 2019, Brukinsa was approved in the US to treat MCL. Brukinsa is the second BeiGene candidate to be commercialized. The company's anti-PD-1 antibody tislelizumab was approved in China, also in late 2019, as a third-line treatment for classical Hodgkin lymphoma (cHL). More details.... Stock Symbols: (NSDQ: BGNE; HK: 06160) Share this with colleagues: // //